{"nctId":"NCT01575873","briefTitle":"Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids","startDateStruct":{"date":"2012-03-28","type":"ACTUAL"},"conditions":["Steroid-induced Osteopor, Glucocorticoid-induced Ostepor"],"count":795,"armGroups":[{"label":"Denosumab","type":"EXPERIMENTAL","interventionNames":["Drug: Denosumab","Drug: Placebo for risendronate"]},{"label":"Risendronate","type":"EXPERIMENTAL","interventionNames":["Drug: Risendronate","Drug: Placebo for denosumab"]}],"interventions":[{"name":"Denosumab","otherNames":["ProliaÂ®"]},{"name":"Placebo for risendronate","otherNames":[]},{"name":"Risendronate","otherNames":["Actonel, Atelvia"]},{"name":"Placebo for denosumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMen and women 18 years of age or older who have been taking glucocorticoid treatment. Men and women who are less than 50 years of age must have had a fracture as an adult to be eligible. Men and women who are 50 years of age or older who have been taking glucocorticoids must meet protocol-specific BMD criteria.\n\nExclusion Criteria:\n\nUse of agents affecting bone metabolism, use of more than one biologic agent for inflammatory disease, history of bone disease (except osteoporosis), low vitamin D level (one can enter the trial after vitamin D levels are corrected), abnormalities of blood calcium, an underactive or overactive thyroid condition that is not treated and stable, Addison's disease, any abnormality of the parathyroid glands (the glands that control blood calcium), currently pregnant or planning a pregnancy, currently breast feeding, and other criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis)","description":"Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"2.3","spread":null},{"groupId":"OG003","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Superiority Analysis)","description":"Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"2.3","spread":null},{"groupId":"OG003","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12","description":"Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"1.7","spread":null},{"groupId":"OG002","value":"0.6","spread":null},{"groupId":"OG003","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 24","description":"Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"6.2","spread":null},{"groupId":"OG002","value":"3.2","spread":null},{"groupId":"OG003","value":"6.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Hip Bone Mineral Density at Month 24","description":"Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":null},{"groupId":"OG001","value":"3.1","spread":null},{"groupId":"OG002","value":"0.5","spread":null},{"groupId":"OG003","value":"2.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":98,"n":385},"commonTop":["Arthralgia","Back pain","Viral upper respiratory tract infection","Hypertension"]}}}